Archive for April, 2023

  • BioData Solutions announces new incorporation of Ariadne Software

    By / News / 0 comments

    Ariadne Software® is committed to maintaining the highest levels of security and data integrity for its customers. On this journey of security and compliance, Ariadne has reached another milestone of ISO/IEC 27001:2013 certification for its information security management system. The ISO 27001 guidance is designed to ensure confidentiality, integrity, and availability of an organization’s and its customers’ data by investing in its people, processes, and technologies.

    0

  • 17th WRIB (Workshop on Recent Issues in Bioanalysis) 2023

    By / Events / 0 comments

    In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

    4

  • CRO Symposium: Exploring The Contract Research Industry & Market

    By / Events / 0 comments

    In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

    4

  • AAPS National Biotechnology Conference (NBC) 2023

    By / Events / 0 comments

    In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

    4